TrianglePUBLICATIONS · 30785198
Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Ann Oncol
- Publication date
- 2019 May 1
- First author
- Kim ST
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Kim ST
- type
- Author
- name
- Kang JH
- type
- Author
- name
- Lee J
- type
- Author
- name
- Lee HW
- type
- Author
- name
- Oh SY
- type
- Author
- name
- Jang JS
- type
- Author
- name
- Lee MA
- type
- Author
- name
- Sohn BS
- type
- Author
- name
- Yoon SY
- type
- Author
- name
- Choi HJ
- type
- Author
- name
- Hong JH
- type
- Author
- name
- Kim MJ
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Kim ST
- type
- Author
- name
- Kang JH
- type
- Author
- name
- Lee J
- type
- Author
- name
- Lee HW
- type
- Author
- name
- Oh SY
- type
- Author
- name
- Jang JS
- type
- Author
- name
- Lee MA
- type
- Author
- name
- Sohn BS
- type
- Author
- name
- Yoon SY
- type
- Author
- name
- Choi HJ
- type
- Author
- name
- Hong JH
- type
- Author
- name
- Kim MJ
- type
- Author
- bibliography ids
- nci-bib-e73fef88a4727f7a4b74ef44
- book metadata
- content sha256
- 79099d642a866d773647d701ca2a9c1d73e8c1455ac2204126115eea63709abd
- document type
- citation
- dois
- 10.1093/annonc/mdz058
- electronic publication date
- display
- Source null
- precision
- missing
- year
- Source null
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:30785198
- immutable id
- pubmed:30785198@79099d642a866d773647d701ca2a9c1d73e8c1455ac2204126115eea63709abd
- journal
- abbreviation
- Ann Oncol
- issn electronic
- 1569-8041
- issn print
- 0923-7534
- issue
- 5
- name
- Annals of oncology : official journal of the European Society for Medical Oncology
- nlm unique id
- 9007735
- pages
- 788-795
- volume
- 30
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 30785198
- provenance
- batch id
- e808962322f3afebc564
- provider
- NCBI PubMed ESummary
- record sha256
- 4bfa4505c68a23720fdb372159ddf5e314331d15ac2131a61561cd460c4723a8
- response sha256
- 3d610336ca8dae92b82cdb6b3ee6cab382eb509e0349b0c68c261b042b036561
- retrieved at
- 2026-09-09T23:47:41.002093+00:00
- publication date
- display
- 2019 May 1
- precision
- day
- year
- 2019
- publication types
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- Equivalence Trial
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial.
Preserved source evidence · Not medical advice